[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
November 10, 2004

Stimulants and Attention-Deficit/Hyperactivity Disorder

Author Affiliations

Letters Section Editor: Robert M. Golub, MD, Senior Editor.

JAMA. 2004;292(18):2214. doi:10.1001/jama.292.18.2214-a

To the Editor: The Contempo Update on attention-deficit/hyperactivity disorder (ADHD) by Dr Wilens and colleagues1 presented pharmacologic treatment options. However, in discussing the use of stimulant medications, the authors did not address risks of addiction, tolerance, or habituation. I would like to know if the authors think that these risks are significant enough to warrant having patients sign a treatment contract acknowledging the risks and the conditions of ongoing care. I would also be interested in whether they think patients receiving stimulant treatment should be evaluated monthly in the office prior to refills and, if not, what other refill mechanisms they would recommend.